1, Yealimi Noh, .79%. 2 (tie), Haeran Ryu and Rio Takeda, .78%. 4 (tie), Akie Iwai and Nanna Koerstz Madsen, .77%. 6 (tie), Allisen Corpuz and Hannah Green, .76%. 8, Lexi Thompson, .75%. 9, Rose Zhang ...

Biopharmas have been scaling back on AAV research for sometime now. Find out why and what's on the horizon for drug delivery ...

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest in gene therapies for the bleeding disorder.” (Pfizer had earlier dumped a ...

Trump said his plan would see the US “pay the same price as the Nation that pays the lowest price anywhere in the World.” ...

President Donald Trump said Sunday night that he will sign an executive order on Monday to cut the cost of prescription drugs ...

China’s exports surged as shipments to Southeast Asian countries soared, offsetting a sharp drop in outbound goods to the U.S ...

Takeda Pharmaceuticals delivered strong FY2024 results and offers value with a 4.81% yield, despite pressure from Vyvanse ...

Q4 2024 Earnings Call Transcript May 9, 2025 Christopher O’Reilly: Thank you very much for taking time out of their busy ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Enhertu delivered a phase 3 trial win in early-stage breast cancer. Takeda spotlighted three late-stage readouts as a ...

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the ...